Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) released a notification on 21 April 2026 confirming that its 2025 Annual Report is now available in both English and Chinese on the company’s website (www.fosunpharma.com) and on HKEX’s website (www.hkexnews.hk).

Registered shareholders who previously chose printed materials will receive hard-copy reports with this mailing. Shareholders preferring hard copies going forward can submit the enclosed reply form to the company’s Hong Kong H-share registrar, Tricor Investor Services Limited, using the prepaid mailing label or by email to is-ecom@vistra.com. FOSUN PHARMA will dispatch requested printed versions free of charge.

The company emphasizes the importance of maintaining a valid email address to receive electronic notifications of future corporate communications and actionable documents. Shareholders who have not provided, or need to update, an email address are urged to complete and return the reply form.

Enquiries can be directed to Tricor’s hotline at (852) 2980 1333, Monday to Friday, 9:00 a.m.-6:00 p.m. (excluding public holidays).

The notice was issued under the authority of the Board and signed by Chairman Mr. Chen Yuqing.